4D Molecular Therapeutics, Inc.
SEC CIK 1650648 · FMDT · last insider filing 2026-06-25
Directors (from insider filings)
| Name | Capacity as filed | Filings |
|---|---|---|
| Kirn David | Director · See Remarks | filed 2020 - 2026 |
| Milligan John F | Director | filed 2020 - 2026 |
| Sblendorio Glenn | Director | filed 2026 - 2026 |
| Chacko Jacob | Director | filed 2020 - 2026 |
| Tomasello Shawn | Director | filed 2020 - 2026 |
| Theuer Charles | Director | filed 2020 - 2026 |
| Miller-Rich Nancy | Director | filed 2020 - 2026 |
| Gray Susannah | Director | filed 2020 - 2026 |
| Kasahara Noriyuki | Director | filed 2022 - 2023 |
| Schaffer David | Director | filed 2020 - 2021 |
| YAO Tony Dung Ling | Director | filed 2020 - 2020 |
| Burkoth William T. | Director | filed 2020 - 2020 |
Officers (from insider filings)
| Name | Title as filed | Filings |
|---|---|---|
| Bizily Scott | Chief Legal and HR Officer | filed 2022 - 2026 |
| Simms Christopher Paul | See Remarks | filed 2025 - 2026 |
| Gupta Ashoo | VP, Finance and Controller | filed 2025 - 2026 |
| Humer Kristian | Chief Financial Officer | filed 2025 - 2025 |
| Kamal Fariborz | See Remarks | filed 2020 - 2025 |
| Mehra Uneek | See Remarks | filed 2023 - 2025 |
| Kim Robert Young | Chief Medical Officer | filed 2023 - 2025 |
| Moretti August J | See Remarks | filed 2020 - 2023 |
| Fishman Robert S | Chief Medical Officer | filed 2020 - 2022 |
| Zimmermann Carolyne | Chief Business Officer | filed 2021 - 2022 |
About this record
From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.
Source: SEC Insider Transactions Data Sets (Forms 3/4/5), US Federal Government public domain.